| 项 目 | 本报告期 | | 上年同期 | | --- | --- | --- | --- | | 归属于上市公司股东的净利润 | | 800.00 | 2,155.50 | | | 比上年同期下降 | 62.89% | | | 扣除非经常性损益后的净利润 | | 120.00 | 1,812.04 | | | 比上年同期下降 | 93.38% | | | 基本每股收益（元/股） | | 0.02 | 0.05 | 证券代码：003040 证券简称：楚天龙 公告编号：2026-004 楚天龙股份有限公司 2025年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025年1月1日至2025年12月31日。 2、业绩预告情况：预计净利润为正值且属于同向下降50%以上情形 （1）以确数进行业绩预告的 单位：万元 四、风险提示 二、与会计师事务所沟通情况 1、本期业绩预告未经注册会计师预审计。 2、公司就本期业绩预告有关事项与会计师事务所进行了预沟通，在业绩预 告方面不存在分歧。 三、业绩变动原因说明 公司20 ...

Financial Projections - The estimated net profit for 2025 is projected to be between -57,000 and -49,000 thousand yuan, representing a year-on-year change of -8.02% to 7.14%[5] - The estimated net profit after deducting non-recurring gains and losses is projected to be between -51,170 and -43,170 thousand yuan, with a year-on-year change of -10.68% to 6.63%[5] - The basic earnings per share is estimated to be between -0.5981 and -0.5141 yuan per share[5] - The earnings forecast period is from January 1, 2025, to December 31, 2025[3] Reasons for Loss - The primary reason for the loss is a significant decline in revenue from existing games, while newly launched games have not contributed significantly to profits due to high development and promotion costs[7] - The company anticipates goodwill impairment related to its subsidiaries, estimating an impact of -90,000 to -130,000 thousand yuan on net profit attributable to shareholders[8] - Changes in the fair value of certain non-current financial assets and investment properties have also negatively impacted profits[8] Financial Disclosure - The financial data in this earnings forecast has not been audited by registered accountants, but there are no significant discrepancies with the auditing firm[6] - The company will disclose detailed financial data in the 2025 annual report[9] - The company emphasizes the importance of timely information disclosure and advises investors to make cautious decisions[9]

Financial Performance Expectations - The company expects a net profit attributable to shareholders to be in the range of -195 million to -130 million CNY for the year 2025, compared to -208.57 million CNY in the same period last year [5]. - The net profit after deducting non-recurring gains and losses is projected to be between -210 million and -145 million CNY, compared to -213.45 million CNY in the previous year [5]. - Basic earnings per share are expected to be between -0.0887 and -0.0591 CNY, compared to -0.0948 CNY in the same period last year [5]. Operational Challenges - The primary reason for the expected loss is the operational losses from certain overseas subsidiaries due to ongoing geopolitical impacts [7]. - Some domestic subsidiaries are still in the construction phase, leading to ineffective capacity release and depreciation on completed facilities, negatively affecting the company's performance [8]. Impairment Provisions - The company has made provisions for impairment losses on other receivables and inventory totaling approximately 66 million CNY, including 16 million CNY for bad debt and 50 million CNY for inventory write-downs [8]. Financial Reporting Status - The financial data presented is preliminary and has not been audited by the accounting firm, with final figures to be disclosed in the 2025 annual report [9].

Financial Performance - The company expects a net profit in the range of -405 million to -305 million CNY for the fiscal year 2025, compared to a net profit of -173.52 million CNY in the same period last year [4]. - The net profit after deducting non-recurring gains and losses is projected to be between -415 million and -315 million CNY, down from -192.06 million CNY year-on-year [4]. - The company faces increased losses due to a contraction in client investment in healthcare information technology, leading to a decline in operating revenue [6]. Product Development and Market Position - The new generation HI-HIS product has been deployed in over 100 hospitals across more than 20 provinces, but its short-term contribution to revenue is limited as it is still in the market introduction phase [7]. - The competitive landscape in the healthcare information technology sector has intensified, compressing profit margins due to aggressive pricing strategies from new entrants [8]. - The company has invested heavily in AI research and development, which has increased costs and further pressured profit margins amid declining revenues [8]. - An impairment test for goodwill is expected to result in a provision of approximately 100 million to 130 million CNY due to underperformance of certain subsidiaries [8]. Strategic Initiatives - The company is focusing on enhancing its core products and optimizing development processes to improve efficiency and quality [9]. - A partnership with Zhejiang University aims to establish a joint laboratory for AI in medicine, focusing on innovative applications and research [9]. - The company is implementing a comprehensive risk management system to address challenges in technology iteration, market competition, and talent retention [10].

证券代码：301051 证券简称：信濠光电 公告编号：2026-003 深圳市信濠光电科技股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 二、与会计师事务所沟通情况 本次业绩预告相关的财务数据未经审计机构审计。公司已就本次业绩预告 相关事项与年报会计师事务所进行了初步沟通，双方不存在重大分歧。 三、业绩变动原因说明 1、受行业竞争日渐激烈的影响，公司玻璃盖板业务 2025 年度业绩下滑， 经营成本大幅上升，毛利率同比下滑导致亏损较多； 2、由于笔电和车载玻璃业务的持续拓展及前期研发投入较大，导致当期 产生亏损； 3、受公司经营战略布局调整影响，公司搬迁部分厂区和重新调配产能， 搬迁成本增加，导致当期亏损较多； 2、业绩预告情况：预计净利润为负值 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | 本报告期 | | | 上年同期 | | --- | --- | --- | --- | --- | | 归属于上市公 ...

Financial Performance - The company expects a net profit in the range of -98 million to -75 million CNY for the fiscal year 2025, marking the first loss since its listing [2]. - Total revenue is projected to be between 245 million and 270 million CNY, a decline from 372.24 million CNY in the previous year, representing a decrease of approximately 34% [3]. - The net profit attributable to shareholders is expected to be between -98 million and -75 million CNY, compared to 240.14 million CNY in the same period last year [3]. Revenue Decline Factors - The company anticipates a decrease in revenue primarily due to a decline in traditional business demand and the strategic decision to abandon certain scattered business contracts [5]. Accounts Receivable Management - The company has formed a special task force to enhance accounts receivable recovery, focusing on improving collection metrics and employing various recovery methods [6]. - The company has noted an increase in the proportion of long-aged accounts receivable, leading to higher bad debt provisions and an increase in impairment losses [6]. Strategic Adjustments - The company is adjusting its market and business strategies, concentrating on key areas such as Shenzhen and Xiong'an, and focusing on core services like total design [5]. Property Valuation Concerns - The fair value of the company's properties is expected to decline due to low occupancy rates and fluctuations in the leasing market [6]. Financial Reporting Disclaimer - The financial data presented is preliminary and subject to uncertainty, with detailed figures to be disclosed in the 2025 annual report [7].

| | | 债券代码：123124 债券简称：晶瑞转 2 晶瑞电子材料股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况 □亏损 扭亏为盈 □同向上升 □同向下降 | 项目 | 本报告期 | | | 上年同期 | | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东 的净利润 | 盈利：12,000 ～ | 万元 | 16,000 | 万元 | 亏损：17,959.38 | 万元 | | 扣除非经常性损益后的 净利润 | ～ 盈利：5,500 | 万元 | 7,500 | 万元 | 亏损：17,100.13 | 万元 | 报告期内，公司业绩变动主要原因如下： 1 1、受益于下游半导体行业快速增长、国产替代进程加快，公司高纯双氧水、 高纯硫酸、高纯氨水、高纯异丙醇等产品销量及销售金额同比大幅增长；光刻胶 产品销量及销售金额稳步提升，其中 ...

Financial Projections - The estimated net profit for the period from January 1, 2025, to December 31, 2025, is projected to be a loss of between 24,000 and 29,000 million yuan, compared to a loss of 24,912.70 million yuan in the same period last year [3]. - The estimated net profit after deducting non-recurring gains and losses is projected to be a loss of between 25,800 and 30,800 million yuan, compared to a loss of 26,339.65 million yuan in the same period last year [3]. - The basic earnings per share is expected to be a loss of between 0.69 and 0.83 yuan per share, compared to a loss of 0.71 yuan per share in the same period last year [3]. Operational Challenges - The primary reason for the expected loss is the imbalance in supply and demand in the broiler chicken industry, with slow capacity reduction and low market prices for chicken products due to intensified competition and insufficient downstream purchasing power [5]. - The company’s main products, including broiler chicks and chicken products, are facing price pressure and low profitability, leading to operational losses [5]. Financial Reporting - The financial data presented is preliminary and has not been audited by the accounting firm, with no significant discrepancies reported between the company and the accounting firm regarding the earnings forecast [4]. - Investors are advised to make cautious decisions and be aware of investment risks due to the preliminary nature of the earnings forecast [6].

本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1.业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 证券代码：000721 证券简称：西安饮食 公告编号：2026-005 西安饮食股份有限公司 2025年度业绩预告 2.业绩预告情况：预计净利润为负值 | 项 目 | | | 本报告期 | | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股 东的净利润 | 亏损：12,000 | | 万元 - | 15,300 | 万元 | 亏损：12,800.51 | 万元 | | | 比上年同期：增长 | | 6.25% | - | 下降 19.53% | | | | 扣除非经常性损益 后的净利润 | 亏损：12,600 | | 万元 - | 15,900 | 万元 | 亏损：13,567.75 | 万元 | | | 比上年同期: | 增长 | 7.13% | - | 下降 17.19% | | | | 基本每股收益 | 亏损 ...

Financial Performance Expectations - The company expects a net loss for the fiscal year 2025, estimated between CNY 39 million and CNY 49 million, compared to a loss of CNY 47.88 million in the previous year[2]. - The projected revenue for 2025 is estimated to be between CNY 520 million and CNY 560 million, down from CNY 571.92 million in the previous year[2]. - The basic earnings per share are expected to be a loss between CNY 0.2535 and CNY 0.3184, compared to a loss of CNY 0.3099 in the previous year[2]. Asset Impairment and Liabilities - The company has identified goodwill impairment risks related to the acquisition of Shanghai Youyi E-commerce Co., Ltd., leading to the recognition of impairment provisions[4]. - There are indications of potential asset impairments in receivables and inventory, prompting the company to make provisions based on prudence[4]. - The company is also recognizing estimated liabilities related to litigation that may impact profits, in accordance with accounting standards[4]. Financial Reporting Status - The financial data presented is preliminary and has not been audited by registered accountants, with final figures to be confirmed in the 2025 annual report[3][5].